Immuneering Corporation
NASDAQ•IMRX
CEO: Dr. Benjamin J. Zeskind M.B.A., Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-07-30
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Contact Information
Market Cap
$152.11M
P/E (TTM)
-3.4
24.5
Dividend Yield
--
52W High
$10.08
52W Low
$1.66
52W Range
Rank44Top 53.8%
3.7
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 3.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025
Deep Research
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data